Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Clinical trial NCT05600686 · RECRUITING

Trial details

NCT number: NCT05600686
Sponsor: University of California, Davis
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Double-Expressor Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Start date: 2023-05-24
Primary completion: 2026-10-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.